PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL after commercial tisagenlecleucel

Bookmark and Share
Published: 16 Dec 2020
Views: 121
Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA

Dr Schultz talks to ecancer about disease burden impacts outcomes in paediatric and young adult B-cell acute lymphoblastic leukaemia after commercial tisagenlecleucel: Results from the paediatric real world CAR consortium (PRWCC). These results were presented at this year’s ASH 2020 virtual conference.

Dr Schultz initially gives an explanation of what PRWCC was and then moves on to explain what this specific study evaluated and how. She says that in this study retrospective data was collected from 15 PRWCC member institutions and included 200 patients.

She then mentions the key results from this study and talks about the future of this research and how it can change the treatment of B-cell acute lymphoblastic leukaemia.

In conclusion she says that this retrospective, multi-institutional analysis describes real world outcomes using tisagenlecleucel to treat paediatric r/r B-ALL.